These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 11775545)
1. Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect. Liu X; Zhang L; Zhang M; Ma Y; Xu X; Cai Y Chin Med J (Engl); 2000 Feb; 113(2):167-71. PubMed ID: 11775545 [TBL] [Abstract][Full Text] [Related]
2. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency. Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic antitumor response to cervical cancer in mice immunized with U14 vaccines transfected with costimulatory B7 gene. Tao G; Hu J; Zou H; Lin Q; Liu F; Wu Y; Sun Q Chin Med J (Engl); 2001 Jun; 114(6):623-7. PubMed ID: 11780440 [TBL] [Abstract][Full Text] [Related]
4. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model. Emtage PC; Wan Y; Bramson JL; Graham FL; Gauldie J J Immunol; 1998 Mar; 160(5):2531-8. PubMed ID: 9498799 [TBL] [Abstract][Full Text] [Related]
5. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Cayeux S; Beck C; Aicher A; Dörken B; Blankenstein T Eur J Immunol; 1995 Aug; 25(8):2325-31. PubMed ID: 7545119 [TBL] [Abstract][Full Text] [Related]
6. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. Guinn BA; DeBenedette MA; Watts TH; Berinstein NL J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049 [TBL] [Abstract][Full Text] [Related]
7. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer. Xiang J; Chen Y; Moyana T Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205 [TBL] [Abstract][Full Text] [Related]
8. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. Cayeux S; Richter G; Noffz G; Dörken B; Blankenstein T J Immunol; 1997 Mar; 158(6):2834-41. PubMed ID: 9058819 [TBL] [Abstract][Full Text] [Related]
9. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Todo T; Martuza RL; Dallman MJ; Rabkin SD Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154 [TBL] [Abstract][Full Text] [Related]
10. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts. Wang J; Nakamoto T; Kasaoka Y; Usui T; Hamada H Hiroshima J Med Sci; 2000 Mar; 49(1):73-82. PubMed ID: 10824460 [TBL] [Abstract][Full Text] [Related]
11. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma. Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650 [TBL] [Abstract][Full Text] [Related]
12. IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Chan L; Hardwick N; Darling D; Galea-Lauri J; Gäken J; Devereux S; Kemeny M; Mufti G; Farzaneh F Mol Ther; 2005 Jan; 11(1):120-31. PubMed ID: 15585413 [TBL] [Abstract][Full Text] [Related]
13. Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity. Si SY; Hu PZ; Huang YY; Ye J; Huang Y; Li ZS; Ge W; Li X; Qu P; Zhang XM; Sui YF Biochem Biophys Res Commun; 2006 Aug; 347(1):208-14. PubMed ID: 16814254 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. Larchian WA; Horiguchi Y; Nair SK; Fair WR; Heston WD; Gilboa E Clin Cancer Res; 2000 Jul; 6(7):2913-20. PubMed ID: 10914741 [TBL] [Abstract][Full Text] [Related]
15. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531 [TBL] [Abstract][Full Text] [Related]
16. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553 [TBL] [Abstract][Full Text] [Related]
17. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Liu A; Hu P; Khawli LA; Epstein AL Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313 [TBL] [Abstract][Full Text] [Related]
19. Construction of expression vector of hTERT- hIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT. Tong XM; Zheng SE; Bader A; Yao HP; Wu NP; Altmeyer P; Brockmeyer NH; Jin J Eur J Med Res; 2008 Jan; 13(1):7-14. PubMed ID: 18226991 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules. Liu Y; Wang H; Zhao J; Ma J; Wei L; Wu S; Xie T; Shen F; Trojan J; Habib N; Anthony DD; Wu M; Guo Y Cancer Gene Ther; 2000 Mar; 7(3):456-65. PubMed ID: 10766352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]